Real World Data in Expanded Access Protocols
Last week, at a conference on Expanded Access Programs, the buzz of the conference focused on how we can incorporate Real World Data into our compassionate use protocols, whether Expanded Access Protocols, Cohort or other. While permissible, we often think twice about the balance of keeping Expanded Access Protocols less burdensome for patients and physicians and the opportunity to collect data to inform. Certainly, compassionate use protocols provide a significant opportunity for collection of Real World Data in a setting that provides a real-world setting. At the conference I spoke to the ‘how’ of planning and executing an Expanded Access Protocol where real world data are collected. Importantly, I spoke to the importance of incorporating the voice of the patient as a partner in the development of these programs. Truly, a perspective of “Patients as Partners” within the context of developing an Expanded Access Protocol that can be operationalized in any multi-patient compassionate use protocol. We already have insights that data generated can be used to support regulatory filings in some countries. One of the areas that I also highlighted was how real-world data is already being extracted from other types of trials, including Pragmatic Clinical Trials. Payors are more open to real world data than ever before. This doesn’t necessarily mean that they will always be willing to pay for a drug that shows clear benefit in these real-world settings, but with the right drug in the right disease we might be able to demonstrate enough benefit in the real world setting that payors would be willing to pay. There are several misunderstood types of trials that can be falsely portrayed as opportunities to collect real world data and ‘buyer beware’ needs to be a mantra I continue to speak.
Early Access Care can help you navigate this landscape and mature a best strategy for real world data collection. Contact us (firstname.lastname@example.org) to assist your program. This journey doesn’t need to remain mysterious and there is plenty of opportunity.
Early Access Care is a sponsor of World Orphan Drug Congress USA 2018, April 25-27, Oxon Hill MD. There will be over 800 leaders in orphan drugs covering all aspects of orphan drug development and rare disease research. We are holding two Round-Table events where we are discussing strategic and cost-effective approaches to real world data in multiple trial types and Expanded Access / Compassionate Use. If you are planning on attending the World Orphan Drug Congress and would like to join this conversation, please let us know (email@example.com).